A study to observe the safety of Bevacizumab when it is added to the standard chemotherapy (carboplatin and paclitaxel)when it is routinely prescribed to patients of advanced/metastatic epithelial ovarian,fallopian tube or primary peritoneal cancer

AN INDIAN MULTICENTRIC OPEN LABEL PROSPECTIVE PHASE IV STUDY OF BEVACIZUMAB IN THE FRONT LINE MANAGEMENT OF ADVANCED/METASTATIC EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CANCER OR PRIMARY PERITONEAL CANCER IN REAL CLINICAL PRACTICE

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2013/05/003627

Enrollment

100

Registered

2013-05-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Advanced/metastatic Epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer

Interventions

Intervention1: It is a data collection study no test product or intervention will be done for the study.: Data will be collected for bevacizumab, that is prescribed as per routine practice i.e 15 mg/k

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are prescribed to receive bevacizumab or are already ongoing on treatment with bevacizumab for Advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage lllb, lllc and lV) according to the routine clinical practice are eligible to enter this non-interventional study. Patients willing and able to give consent to data collection. Age is not defined in the protocol.

Exclusion criteria

Exclusion criteria: There is no specific exclusion criteria for this non-interventional study and patients who are considered not eligible to receive bevacizumab for advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to the local prescribing information will not be enrolled in the study

Design outcomes

Primary

Measure	Time frame
To determine the safety profile (all grade 3 and above adverse events) of bevacizumab when added to standard chemotherapy (carboplatin and paclitaxel) in front line advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) in Indian populationTimepoint: Upto 30 days after last dose of Bevacizumab	—

Secondary

Measure	Time frame
The Secondary objectives for this study are as follows: • Progression free survival (PFS) • Overall survival (OS) • Overall response rates (Complete response (CR)+ Partial response (PR)) • Clinical benefit response rates (CR+PR+ Stable disease(SD)) Timepoint: till end of study (Approx 1st Quarter 2015)	—

Countries

India

Contacts

Public ContactAmol Pawar

Roche Products India Pvt.Ltd

jyotii.poddaar@roche.com9136064373

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026